Wockhardt Ltd. (WOCKPHARMA) fundamentals
Wockhardt Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as WOCKPHARMA (ISIN INE049B01025). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Wockhardt Ltd. does
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Valuation and market data
| Last close | ₹1809.60 |
|---|---|
| Market capitalisation | ₹27,447 crore |
| Enterprise value | ₹28,942 crore |
| P/E (TTM) | 137.93 |
| Price to book | 5.20 |
| Price to sales (TTM) | 4.54 |
| Book value per share | ₹348.17 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Feb 23 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹3,484 crore | ₹238 crore | ₹199 crore | 13.12 |
| Mar 2025 | ₹3,074 crore | ₹-16 crore | ₹-57 crore | -3.02 |
| Mar 2024 | ₹2,881 crore | ₹-420 crore | ₹-472 crore | -32.05 |
| Mar 2023 | ₹2,773 crore | ₹-624 crore | ₹-621 crore | -38.79 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 49.3% |
|---|---|
| Foreign institutions (FII) | 7.0% |
| Mutual funds | 6.0% |
| Other domestic institutions | 1.9% |
| Retail and others | 35.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.